McCabe, C. J., Claxton, K., O'Hagan, A.
Pharmaceutical regulators and health care reimbursement authorities operate in different intellectual paradigms and adopt very different decision rules. As a result drugs that have been licensed are...
The value of implementation and the value of information: combined and uneven development (2008)
Fenwick, E., Claxton, K., Sculpher, M.
Aim: In a budget-constrained health care system, the decision to invest in strategies to improve the implementation of cost-effective technologies must be made alongside decisions regarding...
Bravo Vergel, Y., Hawkins, N. S., Claxton, K., Asseburg, C., Palmer, S., Woolacott, N., ...
Objective. Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). We assess the cost-effectiveness...
Colbourn, T.E., Asseburg, C., Bojke, L., Philips, Z., Welton, N.J., Claxton, K., ...
Objective: To determine the cost effectiveness of strategies for preventing neonatal infection with group B streptococci and other bacteria in the UK and the value of further information from...
Colbourn, T.E., Asseburg, C., Bojke, L., Philips, Z., Welton, N.J., Claxton, K., ...
Objective: To determine the cost effectiveness of strategies for preventing neonatal infection with group B streptococci and other bacteria in the UK and the value of further information from...
Rights, responsibilities and NICE: a rejoinder to Harris (2007)
Harris’ reply to our defence of NICE’s current cost-effectiveness procedures contains two further errors. First, he wrongly draws from the fact that NICE does not and cannot evaluate all possible...
Rights, responsibilities and NICE: a rejoinder to Harris (2007)
Harris’ reply to our defence of NICE’s current cost-effectiveness procedures contains two further errors. First, he wrongly draws from the fact that NICE does not and cannot evaluate all possible...
The report by the Office of Fair Trading (OFT) on the UK pharmaceutical price regulation scheme (PPRS) recommends the reform of the current scheme, which is a combination of profit and price...
Culyer, A., McCabe, C., Briggs, A., Claxton, K., Buxton, M., Akehurst, R., ...
There has been much speculation about whether the National Institute for Health and Clinical Excellence (NICE) has, or ought to have, a'threshold' figure for the cost of an additional...
Fenwick, E., Palmer, S., Claxton, K., Sculpher, M., Abrams, K., Sutton, A.
Purpose. This article presents an iterative framework for managing the dynamic process of health technology assessment. The framework uses Bayesian statistical decision theory and value of...
Wickedness or folly? The ethics of NICE's decisions (2006)
A rebuttal is provided to each of the arguments adduced by John Harris, an Editor-in-Chief of the Journal of Medical Ethics, in two editorials in the journal in support of the view that National...
Philips, Z., Claxton, K., Palmer, S., Bojke, L., Sculpher, M.
The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic...
Orphan drugs revisited.[comment] (2006)
McCabe, C., Tsuchiya, A., Claxton, K., Raftery, J.
Hughes et al.1 recently discussed arguments for and against giving special funding status to orphan drugs in this journal. They concluded that there should be a uniform policy across Europe, that...
Nelson, E.A., O'Meara, S., Craig, D., Iglesias, C., Golder, S., Dalton, J., ...
OBJECTIVES: To review systematically the evidence on the performance of diagnostic tests used to identify infection in diabetic foot ulcers (DFUs) and of interventions to treat infected DFUs. To use...
Defining and characterising structural uncertainty in decision analytic models (2006)
Bojke, L., Claxton, K., Palmer, S., Sculpher, M.
An inappropriate structure for a decision analytic model can potentially invalidate estimates of cost-effectiveness and estimates of the value of further research. However, there are often a number...
Defining and characterising structural uncertainty in decision analytic models (2006)
Bojke, L., Claxton, K., Palmer, S., Sculpher, M.
An inappropriate structure for a decision analytic model can potentially invalidate estimates of cost-effectiveness and estimates of the value of further research. However, there are often a number...
Defining and characterising structural uncertainty in decision analytic models (2006)
Bojke, L., Claxton, K., Palmer, S., Sculpher, M.
An inappropriate structure for a decision analytic model can potentially invalidate estimates of cost-effectiveness and estimates of the value of further research. However, there are often a number...
Evidence Synthesis, Parameter Correlation, and Probabilistic Sensitivity Analysis (2006)
Ades, A.E., Claxton, K., Sculpher, M.
Over the last decade or so, there have been many developments in methods to handle uncertainty in cost-effectiveness studies. In decision modelling, it is widely accepted that there needs to be an...
Objective: To conduct a Bayesian value-of-information analysis of the cost effectiveness of pentoxifylline (vs placebo) as an adjunct to compression for venous leg ulcers. Estimates of the...
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review (2006)
Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K., ...
OBJECTIVE: The aim of this review was to evaluate the clinical effectiveness, safety, tolerability and costeffectiveness of etanercept and infliximab for the treatment of active and progressive...
Orphan drugs and the NHS: Should we value rarity (2005)
McCabe, C., Claxton, K., Tsuchiya, A.
Cost effectiveness plays an important part in current decisions about the funding of health technologies. Drugs for rare disease (orphan drugs) are often expensive to produce and, by definition, will...
Orphan drugs and the NHS: Should we value rarity (2005)
McCabe, C., Claxton, K., Tsuchiya, A.
Cost effectiveness plays an important part in current decisions about the funding of health technologies. Drugs for rare disease (orphan drugs) are often expensive to produce and, by definition, will...
Orphan drugs and the NHS: Should we value rarity (2005)
McCabe, C., Claxton, K., Tsuchiya, A.
Cost effectiveness plays an important part in current decisions about the funding of health technologies. Drugs for rare disease (orphan drugs) are often expensive to produce and, by definition, will...
The value of implementation and the value of information: combined and uneven development (2005)
Fenwick, E., Claxton, K., Sculpher, M.
Aim: In a budget constrained healthcare system the decision to invest in strategies to improve the implementation of cost-effective technologies must be made alongside decisions regarding investment...
The value of implementation and the value of information: combined and uneven development (2005)
Fenwick, E., Claxton, K., Sculpher, M.
Aim: In a budget constrained healthcare system the decision to invest in strategies to improve the implementation of cost-effective technologies must be made alongside decisions regarding investment...
The value of implementation and the value of information: combined and uneven development (2005)
Fenwick, E., Claxton, K., Sculpher, M.
Aim: In a budget constrained healthcare system the decision to invest in strategies to improve the implementation of cost-effective technologies must be made alongside decisions regarding investment...
A pilot study of value of information analysis to support research recommendations for NICE (2005)
Claxton, K., Eggington, S., Ginnelly, L., Griffin, S., McCabe, C., Philips, Z., ...
Background: This project developed as a result of the activities of the Research Teams at the Centre for Health Economics, University of York, and ScHARR at the University of Sheffield in the methods...
A pilot study of value of information analysis to support research recommendations for NICE (2005)
Claxton, K., Eggington, S., Ginnelly, L., Griffin, S., McCabe, C., Philips, Z., ...
Background: This project developed as a result of the activities of the Research Teams at the Centre for Health Economics, University of York, and ScHARR at the University of Sheffield in the methods...
A pilot study of value of information analysis to support research recommendations for NICE (2005)
Claxton, K., Eggington, S., Ginnelly, L., Griffin, S., McCabe, C., Philips, Z., ...
Background: This project developed as a result of the activities of the Research Teams at the Centre for Health Economics, University of York, and ScHARR at the University of Sheffield in the methods...
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra (2005)
Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H., Akehurst, R., Buxton, M., ...
Recently the National Institute for Clinical Excellence (NICE) updated its methods guidance for technology assessment. One aspect of the new guidance is to require the use of probabilistic...
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. (2005)
Claxton, K., Sculpher, M., McCabe, C., Briggs, A., Akehurst, R., Buxton, M., ...
Recently the National Institute for Clinical Excellence (NICE) updated its methods guidance for technology assessment. One aspect of the new guidance is to require the use of probabilistic...
Using value of information analysis to inform publicly funded research priorities (2005)
Ginnelly, L., Claxton, K., Sculpher, M.J., Golder, S.
Introduction: The purpose of this article is to demonstrate the application and feasibility of using value of information analysis to help set priorities for research as part of the UK National...
Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R., ...
BACKGROUND: Decision-analytic models represent an explicit way to synthesise evidence currently available on the outcomes and costs of alternative (mutually exclusive) healthcare interventions....
Health Technology Assessment (2004)
Z Philips, L Ginnelly, M Sculpher, K Claxton, S Golder, R Riemsma, ...
of guidelines for good practice in decision-analytic modelling in health
Chilcott, J., McCabe, C., Tappenden, P., O'Hagan, A., Cooper, N.J., Abrams, K., ...
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in...
Chilcott, J., McCabe, C., Tappenden, P., O'Hagan, A., Cooper, N.J., Abrams, K., ...
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in...
Chilcott, J., McCabe, C., Tappenden, P., O'Hagan, A., Cooper, N.J., Abrams, K., ...
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in...
Fenwick, E., Wilson, J., Sculpher, M.J., Claxton, K.
Objective: To compare the cost and cost-effectiveness of a policy of pre-operative optimisation of oxygen delivery (using either adrenaline or dopexamine) to reduce the risk associated with major...
A Dynamic Programming Approach to Efficient Clinical Trial Design (2001)
If the prospective evaluation of all feasible strategies of patient management is not possible or efficient then this poses a number of questions: (i) which clinical decision problems will be worth...
Claxton, K., Neumann, P.J., Araki, S., Weinstein, M.C.
A framework is presented that distinguishes the conceptually separate decisions of which treatment strategy is optimal from the question of whether more information is required to inform this choice...
Bayesian approaches to technology assessment and decision making (2001)
Luce, B.R., Shih, Y.T., Claxton, K.
[FIRST PARAGRAPH] Until the mid-1980s, most economic analyses of healthcare technologies were based on decision theory and used decision-analytic models. The goal was to synthesize all relevant...
Claxton, K., Neumann, P.J., Araki, S., Weinstein, M.C.
A framework is presented that distinguishes the conceptually separate decisions of which treatment strategy is optimal from the question of whether more information is required to inform this choice...
Bayesian approaches to technology assessment and decision making (2001)
Luce, B.R., Shih, Y.T., Claxton, K.
[FIRST PARAGRAPH] Until the mid-1980s, most economic analyses of healthcare technologies were based on decision theory and used decision-analytic models. The goal was to synthesize all relevant...
Claxton, K., Neumann, P.J., Araki, S., Weinstein, M.C.
A framework is presented that distinguishes the conceptually separate decisions of which treatment strategy is optimal from the question of whether more information is required to inform this choice...
Bayesian approaches to technology assessment and decision making (2001)
Luce, B.R., Shih, Y.T., Claxton, K.
[FIRST PARAGRAPH] Until the mid-1980s, most economic analyses of healthcare technologies were based on decision theory and used decision-analytic models. The goal was to synthesize all relevant...
Performance of an electromagnetic lead/scintillating-fibre calorimeter for the H1 detector (1995)
Tomasi, E., Hajduk, T., Janczur, L., Rybicki, W., Claxton, K., Dowdell, B., ...
Performance of an electromagnetic lead/scintillating-fibre calorimeter for the H1 detector (1995)
Tomasi, E., Hajduk, T., Janczur, L., Rybicki, W., Claxton, K., Dowdell, B., ...
Performance of an electromagnetic lead/scintillating-fibre calorimeter for the H1 detector (1995)
Tomasi, E., Hajduk, T., Janczur, L., Rybicki, W., Claxton, K., Dowdell, B., ...
Performance of an electromagnetic lead/scintillating-fibre calorimeter for the H1 detector (1995)
Tomasi, E., Hajduk, T., Janczur, L., Rybicki, W., Claxton, K., Dowdell, B., ...
Performance of an electromagnetic lead/scintillating-fibre calorimeter for the H1 detector (1995)
Tomasi, E., Hajduk, T., Janczur, L., Rybicki, W., Claxton, K., Dowdell, B., ...
Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease
K. Claxton, P. J. Neumannn, S. S. Araki, M. C. Weinstein
A framework is presented which distinguishes the conceptually separate decisions of which treatment strategy is optimal from the question of whether more information is required to inform this choice...
An epidemiological study of petroleum refinery employees.
Wong, O, Morgan, R W, Bailey, W J, Swencicki, R E, Claxton, K, Kheifets, L
A cohort study of 14179 current and former Chevron USA employees at the Richmond and El Segundo, California, refineries was conducted. The cohort consisted of everyone working at either refinery for...
Fenwick, E., Wilson, J., Sculpher, M.J., Claxton, K.
Objective: To compare the cost and cost-effectiveness of a policy of pre-operative optimisation of oxygen delivery (using either adrenaline or dopexamine) to reduce the risk associated with major...
The value of implementation and the value of information: combined and uneven development
Fenwick, E., Claxton, K., Sculpher, M.
Aim: In a budget-constrained health care system, the decision to invest in strategies to improve the implementation of cost-effective technologies must be made alongside decisions regarding...
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H., Akehurst, R., Buxton, M., ...
Recently the National Institute for Clinical Excellence (NICE) updated its methods guidance for technology assessment. One aspect of the new guidance is to require the use of probabilistic...
Fenwick, E., Palmer, S., Claxton, K., Sculpher, M., Abrams, K., Sutton, A.
Purpose. This article presents an iterative framework for managing the dynamic process of health technology assessment. The framework uses Bayesian statistical decision theory and value of...
Wickedness or folly? The ethics of NICE's decisions
A rebuttal is provided to each of the arguments adduced by John Harris, an Editor‐in‐Chief of the Journal of Medical Ethics, in two editorials in the journal in support of the view that National...